Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Theranostics of Neuroendocrine Tumors: Bibliometric Study Based on Web of Science Database

Qi Wang
,
Damiano Librizzi
ORCID logo ,
Shamim Bagheri
,
Ali Ebrahimifard
ORCID logo ,
Azimeh Hojjat Shamami
,
Friederike Eilsberger
ORCID logo ,
Markus Luster
,
Behrooz Hooshyar Yousefi
* ORCID logo
Version 1 : Received: 2 September 2024 / Approved: 2 September 2024 / Online: 3 September 2024 (08:05:24 CEST)

How to cite: Wang, Q.; Librizzi, D.; Bagheri, S.; Ebrahimifard, A.; Hojjat Shamami, A.; Eilsberger, F.; Luster, M.; Hooshyar Yousefi, B. Theranostics of Neuroendocrine Tumors: Bibliometric Study Based on Web of Science Database. Preprints 2024, 2024090201. https://doi.org/10.20944/preprints202409.0201.v1 Wang, Q.; Librizzi, D.; Bagheri, S.; Ebrahimifard, A.; Hojjat Shamami, A.; Eilsberger, F.; Luster, M.; Hooshyar Yousefi, B. Theranostics of Neuroendocrine Tumors: Bibliometric Study Based on Web of Science Database. Preprints 2024, 2024090201. https://doi.org/10.20944/preprints202409.0201.v1

Abstract

Compared to agonists, radiolabeled somatostatin receptor (SSTR) antagonists have advantages in neuroendocrine tumors (NETs). Articles on radiolabeled somatostatin receptor agonists or antagonists in NETs were included by searching the Web of Science (WoS) database. The included literature has been subjected to data collection and bibliometric study. A detailed analysis of the included clinical articles was also performed. 123 publications were identified for biblio-metric analysis. The number of publications on radiolabeled somatostatin receptor agonists and antagonists in the theranostics of NETs has increased significantly after 2014, with Germany publishing the most papers (39), followed by the United States (33) and Switzerland (28). The Swiss paper was cited the most, with 1783 quotations, followed by the USA (1338) and Germany (1330). The most common keywords were NETs (89), Peptide receptor-mediated radionuclide therapy (PRRT) (62), and antagonists (53). Antagonists had lower uptake in normal tissue and higher uptake in tumor tissue compared to agonists, with a high tumor-to-liver ratio. Research on radiolabeled somatostatin receptor agonists and antagonists in theranostics of NETs is increasing, with significant contributions from Europe and the United States. Radiolabeled somatostatin receptor antagonists are likely to be a hot topic in NETs theranostics.

Keywords

Neuroendocrine tumors; theranostics; somatostatin receptor; agonists; antagonists; bibliometric study

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.